Key clinical point: High-flow nasal cannula (HFNC) oxygen therapy had a similar rate of treatment failure but was considered better tolerated than noninvasive ventilation (NIV) among patients with COPD receiving treatment after being extubated because of hypercapnic respiratory failure.
Major finding: The investigators found 22.7% of patients in the HFNC group and 28.6% in the NIV group experienced treatment failure (risk difference, –5.8%; 95% confidence interval, −23.8 to 12.4%; P = .535).
Study details: A multicenter, randomized controlled trial of 96 patients with COPD and hypercapnic respiratory failure who received either HFNC or NIV post extubation.
Disclosures: This study was funded by the Rui E special fund for emergency medicine research and the Yangzhou Science and Technology Development Plan. The authors report no relevant conflicts of interest. Dr. Bowton reports no relevant conflicts of interest.
Tan D et al. Crit Care. 2020 Aug 6. doi: 10.1186/s13054-020-03214-9.